IMPORTANCE Preliminary cost-effectiveness analyses of proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) were based on benefits estimated from reductions in low-density lipoprotein cholesterol that occurred in PCSK9i trials with variable results. The recent Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) trial provides better information about the effectiveness of the drug.
I n the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) trial, 1 the addition of evolocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) drug, to statin therapy was associated with a 59% greater reduction in low-density lipoprotein cholesterol and a 15% lower rate of major adverse cardiovascular events per year (cardiovascular deaths, myocardial infarctions, and stroke) over therapy with statins alone. Despite its effect on cardiovascular risk, there are substantial concerns about the high cost of evolocumab, which is $14 300 per year, and its value to the health care system. Recent studies assessing cost-effectiveness over a lifetime of treatment at current drug prices have shown that PCSK9i drugs were expensive from a health system perspective and were above the societal threshold of $100 000 per quality-adjusted life-year (QALY). [2] [3] [4] [5] Using the recent FOURIER trial results, we determined the health system perspective on the cost-effectiveness of adding PCSK9i to statin therapy. We also projected the return on investment (ROI) for the US private and multipayer insurance market, adding a private payer's viewpoint, which has been lacking thus far, to our knowledge.
Methods
We used a Markov model to complete a cost-effectiveness analysis of 2 lipid-lowering strategies, statin plus PCSK9i vs statin alone, over a time horizon of a lifetime. Our research group have previously described the model in detail. 3 Table 1 reports the parameters used in this cost-effectiveness analysis. The model used a hypothetical cohort of 1000 patients that resembled the FOURIER population as our baseline group. Longitudinal cost parameters for myocardial infarction, stroke, unstable angina, and transient ischemic attack were obtained from the literature. 12 We used observed cardiovascular risk reductions from the FOURIER study 1 f o ru pt o3
years. For all cardiovascular events, we assumed a 1-year probability of 3.7% for patients treated with statin only and a probability of 3.1% for those using statin plus PCSK9i (relative risk [RR] , 0.84). We used a 2-year cardiovascular event probability of 6.8% and 5.5% (RR, 0.81) and a 3-year probability of 9.9% and 7.9% (RR, 0.80) for those using a statin only and those using a statin plus PCSK9i, respectively. We projected cardiovascular risk reductions beyond the duration of the trial by using the Framingham risk functions 6 and imposing a constant RR restriction. The implicit assumption is that a ratio of the annual probability of a cardiovascular event is equivalent to 0.81 after the third year. Our model assumes no difference between treatment strategies for mortality risk after a cardiovascular event.
Comparison between the hazard ratios of outcomes predicted by our model and those observed in FOURIER are presented in the Supplement. We used the current drug price, which is $14 300 a year. We assumed that the future price of PCSK9i would be affected by the entry of generic drugs into the market and would therefore drop by 43% after 12 years of patent protection, the average reduction of specialty drug prices. 15 Costs were reported in 2016 US dollars. All outcomes were discounted at a 3% discount rate.
Finally, we performed a sensitivity analysis that considered coronary revascularization as an additional cardiovascular event. Coronary revascularization is not an outcome, but rather a procedure; however, FOURIER incorporated it as a primary outcome. 1 We initially followed previous studies that did not include coronary revascularization as a cardiovascular event, 2,5 but we analyzed its economic impact in an alternative scenario. We also considered scenarios of permanent patent protection and a 10% increase in cardiovascular event costs in RR reduction and in QALYs. Next, we examined the financial implications of PCSK9i from a private payer's perspective by calculating the net present value (NPV) and ROI over a lifetime. In contrast with some national health systems, the United States has a multipayer insurance market that includes private payers. As a result, not all savings (eg, avoided costs) of PCSK9 inhibitor use will necessarily accrue to individual payers. Payers might therefore be reluctant to fund costly preventive treatment; because 12.2% of insurance plan members switch plans every year, 14 insurers do not accrue all long-term benefits of their investment in these members. However, payers may obtain benefits from premium gains if patients live longer, which results in their contributing to the private payer's premium revenue stream over a longer span of time. They can also obtain benefits by sharing treatment costs with patients via deductibles and copayments. We projected the NPV as the net of the present value of the payer's premium income stream, including a patient's cost sharing component, minus health expenditure costs. The ROI was calculated as the NPV divided by the treatment cost. An ROI or NPV of less than 0 indicates a net loss; an ROI or NPV of greater than 0 indicates a net monetary gain to the payer. Details of the cost projections and assumptions about insurance plans have been previously described. 3 To account for uncertainty in model parameters, we conducted probabilistic sensitivity analysis. Model parameters
Key Points
Question What cost-effectiveness parameters for a statin plus proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor treatment strategy, compared with a statin alone strategy, can be elucidated from the results from the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) trial?
Findings Per a Markov decision model, the incremental cost-effectiveness ratio was $337 729 per quality-adjusted life year at the current PCSK9 inhibitor treatment price of $14 300 per year, and PCSK9 inhibitors were associated with a negative return on investment of 86% for private payers. A price reduction to $5459 a year (a 62% discount) would permit PCSCK9 inhibitor drug therapy to reach the willingness-to-pay threshold of $100 000 per quality-adjusted life-year.
Meaning Based on current pricing and the FOURIER trial results, the addition of a PCSK9 inhibitor to statin therapy is more than 3 times the commonly accepted willingness-to-pay threshold. were assigned β and normal probability distributions. In addition, cost-effectiveness acceptability curves were constructed at different PCSK9i prices. Acceptability curves demonstrate the probability that PCSK9i would be cost effective at different thresholds of society's willingness to pay.
Results
At the current price of $14 300 a year, the incremental costeffectiveness ratio (ICER) of the addition of PCSK9i to statins per the FOURIER results 1 was $337 729 per QALY ( Table 2) .
From a health system perspective, our threshold analysis found that PCSK9i would be cost effective if the price dropped below $5459 a year, the point at which it reached the willingnessto-pay level of $100 000 per QALY. This is 62% lower than the current price. The ROI analysis suggested that, at current prices, PCSK9i would produce a negative ROI of 86%, indicating that for every dollar invested, private insurers would lose $1.86. In dollar terms, putting 1 more plan patient on PCSK9i would produce an NPV loss of $35 907 to the payer. A price lower than $2381 would obtain a positive ROI and NPV.
The uncertainty analysis suggests that, at the current price of $14 300, PCSK9i drugs have less than 1% probability of meeting the $100 000 per QALY threshold generally considered acceptable (Figure) . If the price of PCSK9i were $5000, the probability of the drugs being cost effective would increase to 68%.
Finally, our sensitivity analysis showed that our results are highly sensitive to the patent protection assumption, the PCSK9i cardiovascular risk reduction assumption, and the coronary revascularization assumption. Specifically, ICER increased by 47% , or $496 936 per QALY, under permanent patent protection; decreased by 33%, or $226 653 per QALY, if cardiovascular risk reduction increased by 10%; and decreased by 24%, or $257 119 per QALY, if revascularization was included as a cardiovascular event.
Discussion
This cost-effectiveness analysis of PCSK9i was based on a lower-than-expected reduction in the major cardiovascular events from the FOURIER trial. 1 We found that the addition of PCSK9i to statin therapy is currently priced at more than 3 times the accepted societal cost-effectiveness threshold. To be cost effective, the price of PCSK9i drugs would likely require a decrease of 62%, to $5459 per year, or more. Wider use of the drugs at current prices would create major financial losses. Treating 1 more plan patient with PCSK9i would produce a NPV loss of $35 907, which would be either assumed by the payer or transferred to plan patients via higher premiums. Only when the price dropped by 83%, to $2381 per year, would PCSK9i be financial viable for private payers. Prior cost-effectiveness analyses found PCSK9i to exceed the acceptable societal threshold of $100 000 per QALY. [2] [3] [4] [5] However, none of these studies integrated discounts in drug prices with the expected expiration of patents and the possible introduction of generic versions of drugs. Our study, in contrast, was based on observed event rates in the intermediate term, as well as expected changes in drug costs over time. Abbreviations: ICER, incremental cost-effectiveness ratio; NA, not applicable; NPV, net present value; PCSK9i, proprotein convertase subtilisin/kexin type 9 inhibitor drug; QALY, quality-adjusted life-years; ROI, return on investment.
a The baseline case is defined as a PCSK9i price of $14 300, with 12 years of patent protection followed by a 43% price reduction.
b Incremental cost of treating hyperlipidemia with PCSK9i plus statin compared with statin only. For the private payer, this cost excludes patient cost sharing (see insurance parameters in Table 1 ).
c Incremental cost of CVD events.
d Incremental gain in premium revenues that result from living longer and spending more time contributing to the private payer's premium revenue stream.
e ICER equals treatment costs minus savings (avoided costs).
f NPV equals savings plus premium gains minus treatment cost.
g ROI equals NPV divided by treatment cost.
h The threshold price corresponds to the annual PCSK9i price that makes the ICER equal to $100 000 per QALY.
i The break-even price is the annual PCSK9i price that makes ROI equal to 0.
j Relative risk, costs, and utilities for this scenario are as reported in Table 1. k A scenario in which the risk reduction of cardiovascular events under PCSK9i is assumed to be 10% higher than in Table 1 because of higher PCSK9i efficacy.
l A scenario assuming a higher health utility for the average person in the cohort replicating the FOURIER PCSK9i trial population.
The findings are consistent with the more conservative preliminary assessments.
2,4,5
Furthermore, while previous studies did not include coronary revascularization as a cardiovascular event, 2 our sensitivity analysis did include it. Adding revascularization into the model as an outcome reduced the ICER to $257 119 per QALY. Finally, our study provides critical insights on the breakeven price for private payers, which is extremely relevant for the US private, multipayer, insurance market. Our findings suggest that even greater discounts will be necessary for PCSK9i to be a financially sound investment for insurers. Because private payers might face the majority of the up-front investment but only a fraction of the long-term benefits, extensive deliberations are needed to identify the right financial incentives to overcome access barriers to these emerging interventions.
Limitations
As is inherent to any decision analysis model, our methodology is limited by the simplifying assumptions about the underlying cohort that we used in analysis, which might not represent the US population accurately. This study is best thought of as applicable to a hypothetical baseline population that resembles the FOURIER trial participants. 1 Additional factors that might have influenced the effect of PCSK9 inhibitors on total health expenditures include known factors, such as comorbidities and socioeconomic disparities, as well as use of highintensity statins or ezetimibe, a second-line drug used as a substitute for or in addition to statins. The use of ezetimibe might lower the number of patients eligible for PCSK9i use. Finally, this study is not directive about who should be treated, but can only put in perspective costs and effectiveness parameters based on the recent FOURIER trial.
Conclusions
In conclusion, based on current PCSK9i prices and benefit estimates from the FOURIER trial, 1 a price reduction of 62% to 83% is essential for PCSK9i drugs to meet the current societal thresholds of cost-effectiveness and become financially viable for private payers. Dotted lines signify permanent patent protection of proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) drugs, while solid lines signify patent protection that lapses after 12 years, leading to a 43% reduction in price. (a) Treatments were PCSK9i (cost $14,300/year) plus statin therapy (cost $267/year) 1 , or statin only therapy (usual care). We considered a baseline treatment cost of $13,515/year 2 ; baseline health utility: 0.79 3 . For the private payer perspective, we considered that at the treatment, CV and post-CVD states, individuals pay an insurance premium equivalent to the average premium of the private individual health insurance plans when members were 57-64 years old. When they turned 65, they were assumed to be in a Medicare Advantage plan. We assumed a monthly premium of $520 for age 57-64 years old 4 , and $835 for 65 or older 5 . We also assumed a cost-sharing component. Statins were assumed as tier 1 drugs and PCSK9 inhibitors as tier 2 drugs. No copayments/coinsurance for visits to providers were assumed. We considered average insurance drug copayment and deductible from private individual health insurance plans when individuals were 57-64 years. Drug monthly copayments were assumed at $11 for statins and $31 for PCSK9, and an annual deductible of $3,731 was assumed for this age group 6 . For individuals 65 years old or older, we considered average Medicare Advantage plan cost-sharing. We assumed a drug monthly copayment of $5 for statins and $11 for PCSK9, and an annual deductible of $2,158 for this age group 2 . Health utilities converge to baseline at fifth year. When coronary revascularization was included, we considered it with a second-year cost of $7,379/year and health utility of 0.79 3 . (d) Death (absorbent state). We considered an incremental cost of fatal CVD events of $13,145/year 2 . Health utility for death was equal to 0. For the private payer perspective, we considered that leaving the insurance plan meant an elimination of the premium revenue stream. (e) We used the 1-to-3-year relative risk reduction of CVD events reported in the FOURIER study, including unstable angina and transient ischemic attack for other CVD events 7 . To project annual probabilities of CVD events beyond the third year, we used the baseline survival function from the 10-year Framingham study, under the assumption that the Framingham survival function is proportional to the unobserved evolocumab survival function 8 . One-year probabilities of CVD events were obtained separately for males and females for each CVD event (MI, stroke and other CVD) based on FOURIER CVD event distribution. Probabilities were then combined based on female-male FOURIER distribution. Annual risk of incident cardiovascular disease events for MI, stroke and other CVD were 3.1-11.9% for PCSK9i intervention (age-dependent), and 3.7-14.7% for statin only intervention (age-dependent). (f) Survival of incident cardiovascular disease event was calculated (tunnel states). The transition to post-CVD event occur after one cycle (one year) with probability 1. Progression within post-CVD event (tunnel state) assumes that individuals remain in the post-CVD event for 5 years, implying that it takes 5 years to recuperate from the CVD event. At any time during that 5-year period, they can transit to a subsequent CVD event (b) or they can die (d). (g) One-year probability of subsequent CVD events were obtained from 4-year follow-up
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Framingham study on subsequent CVD events 9 . 1-year probabilities of CVD events were obtained separately for males and females for each CVD event (MI, stroke and other CVD) based on the 2008-2010 average of CVD distribution by age 10 . Probabilities were then combined based on FOURIER female-male distribution. Annual risk of subsequent cardiovascular disease events for MI, stroke and other CVD were 3.4-11.9% for the PCSK9i intervention (age-and time-dependent), and 4.0-14.7% for the statin only intervention (ageand time-dependent). (h) Transition to death (absorbing state) assumes a non-CVD mortality rate of 0.5-18.3% (agedependent). These were obtained from the 2010 U.S. life tables 10 . CVD mortality rates at first year (after MI, stroke or other CVD) were 6.3-100% (age-dependent) 11, 12 . CVD mortality at second-to-fifth year were 2.9-67.3% (age-and time-dependent) 11, 12 . For the private payer perspective, we considered an annual insurance turnover rate of 12.2%
13 . (i) Return to baseline risk after 5 years of cardiovascular disease (calculated).
Output
For the health system perspective, we report 3 outputs (see Table 2 in main document): i) the treatment cost or incremental cost of treating hyperlipidemia with PCSK9i plus statin compared to statin only. ii) the savings or avoided cost of CVD events. Avoided CVD events translate into savings in the long-run. iii) Quality-Adjusted Life Years (QALY) were obtained by multiplying the number of individuals in each health state by its correspondent health utility. Gains in QALYs and life years were obtained by comparing outcomes of treating hyperlipidemia with PCSK9i plus statin compared to statin only All outputs were discounted over lifetime at a 3% discount rate.
The incremental cost-effectiveness ratio (ICER) is equivalent to treatment costs net of gains for avoided costs, divided by QALYs. For example, for the baseline case (see table 2 For the private payer perspective, we report 3 outputs (see Table 2 in main document): i) the investment in PCSK9i (treatment cost) that excludes patient cost-sharing. ii) the avoided costs excluding the fraction of savings that private payers do not accrue because of members who shift out of the plan every year. iii) incremental gain in premium revenues that resulted from living longer and staying more time contributing to the private payer's premium revenue stream.
The NPV is equivalent to net gains minus investment. For example, for the baseline case (see 
Validation
Validation to judge the accuracy of the Markov model predictions are limited in this type of simulation models. However, we used the key findings over the 3 years of data reported by the FOURIER study 7 to compare with the implicit hazard ratios predicted by our model at year 3. The table below shows end points reported in Table 2 of Sabatine et al. 2017 paper and the corresponding values from our model. Our results are reassuring as the 3-year predicted hazard ratio values fall within the FOURIER confidence intervals, suggesting that the simulated cohort is similar to FOURIER. The only outcome where our model under predicts FOURIER is cardiovascular death, which was not statistically significant in FOURIER. Our model predicts cardiovascular mortality after an MI and Stroke event using evidence from previous RCTs 11, 12 . while the result from FOURIER are affected by i) including other cardiovascular deaths with hazard ratio of 1.10 (0.90-1.35) and ii) being still underpowered for mortality outcomes given the short period of time.
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